Tonix Pharmaceuticals Holding Corp (TNXP)

2.99
0.14 4.90
NASDAQ : Health Care
Prev Close 2.85
Open 2.90
Day Low/High 2.86 / 3.01
52 Wk Low/High 1.84 / 8.95
Volume 72.95K
Avg Volume 107.70K
Exchange NASDAQ
Shares Outstanding 7.51M
Market Cap 23.50M
EPS -15.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tonix Pharmaceuticals Presented Retrospective Analyses Of Treatment Response And Remission To TNX-102 SL In A Phase 2 Military-Related PTSD Study

Highlights of these Important Findings from AtEase Presented in Pipeline Presentation at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

Tonix Pharmaceuticals To Present Additional Clinical Results Of Military-Related PTSD Study At The 2017 American Society Of Clinical Psychopharmacology Annual Meeting

Important Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy TNX-102 SL in PTSD will be Highlighted

Tonix Pharmaceuticals Presented Analyses Of Potential Moderators Of Treatment Response To U.S. FDA-Designated Breakthrough Therapy For PTSD, TNX-102 SL, In Phase 2 AtEase Study In Military-Related PTSD

Additional Important Findings Presented in Poster Session at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry

Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides Programs Update

Phase 3 HONOR Study of U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, Fully Funded and Currently Enrolling

Tonix Pharmaceuticals To Present PTSD Clinical Data At The Society Of Biological Psychiatry 72nd Annual Scientific Convention

Additional Results to be Presented from Phase 2 Study of US FDA-Designated Breakthrough Therapy, TNX-102 SL, in PTSD

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For TNX-102 SL Composition And Formulation: Designed For Transmucosal Absorption And Bedtime Daily Use

TNX-102 SL is an FDA-Designated Breakthrough Therapy for PTSD in Phase 3 Development

Tonix Pharmaceuticals Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder

Registration of TNX-102 SL Could be Solely Supported by the Phase 3 HONOR Study if Topline Data are Statistically Persuasive

Tonix Pharmaceuticals To Present FDA Breakthrough Therapy-Designated PTSD Program At The MicroCap Conference

Phase 3 HONOR Study of TNX-102 SL in Military-Related PTSD is Enrolling

Tonix Pharmaceuticals Enrolls First Participant In Military-Related PTSD Phase 3 Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL

HONOR Study to Enroll 550 Participants in Approximately 35 U.S. Sites with One Unblinded Interim Analysis at Approximately 275 Participants

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL

Patent Will Provide Intellectual Property Protection until 2034 to TNX-102 SL, an FDA-Designated Breakthrough Therapy in Phase 3 Development for Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus

Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801 May Qualify for Priority Review Voucher if FDA-Approved Under Provisions in the 21st Century Cures Act

Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At NobleCon13

Tonix Pharmaceuticals To Present Breakthrough Therapy Designated-PTSD Program And Corporate Update At NobleCon13

TNX-102 SL, a Phase 3 drug candidate, recently granted Breakthrough Therapy designation by the FDA; Pivotal study in military-related PTSD to begin this quarter